SOX2 and breast carcinoma: Increased expression of SOX2 correlates with poor prognosis in stage I lung adenocarcinoma [135], esophageal squamous cell carcinoma [136, 137], gastric carcinoma [138–140], small-cell lung carcinoma [141–143], breast cancer [144], testicular tumors [145], and ovarian carcinoma [146].